Use of a novel high-osmolar gadolinium chelate, gadobutrol, for percutaneous renal artery stenting in two patients with chronic renal failure.
Gadolinium chelates have been recently proposed and preliminarily tested as contrast agents for diagnostic and interventional angiography in alternative to iodinated media. However, in most studies low-osmolarity agents were employed and digital subtraction was required for satisfactory images. In this article, we report for the first time in the literature two cases of successful percutaneous renal artery stenting in which gadobutrol, a high-osmolar (1 mmol/ml) gadolinium chelate, was employed as contrast agent because of chronic renal failure and substantial risk for iodinated contrast-associated nephrotoxicity. In both patients gadobutrol yielded high-quality images without digital subtraction and was well tolerated with no ensuing renal dysfunction.
Carlo
C
Trani
Francesco
F
Burzotta
Giuseppe G L
GG
Biondi-Zoccai
Enrico
E
Romagnoli
Francesca A
FA
Gabrielli
Antonio
A
Abbate
Vito
V
Ramazzotti
Flavia
F
Belloni
Giovanni
G
Schiavoni
Rocco
R
Mongiardo
Filippo
F
Crea
Mario A
MA
Mazzari
D000368:Aged; D015901:Angiography, Digital Subtraction / Q000379:methods*; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000000981:diagnostic imaging / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D009994:Osmolar Concentration; D012077:Renal Artery / Q000000981:diagnostic imaging / Q000601:surgery*; D012449:Safety; D015607:Stents
D009942:Organometallic Compounds; C090600:gadobutrol